Snapshot from Jul 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics Securities Fraud Lawsuits
Regulatory securities fraud lawsuit

ADMA Biologics Securities Fraud Lawsuits

Analysis based on 301 articles · First reported Apr 01, 2026 · Last updated Jul 05, 2026

Sentiment
-70
Attention
6
Articles
301
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market has reacted negatively to the allegations against ADMA Biologics, with its stock price plummeting significantly. The ongoing investigations and class action lawsuits by multiple law firms, including Bleichmar Fonti & Auld LLP, Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Rosen Law Firm, Kahn Swick & Foti, and The Schall Law Firm, indicate a prolonged period of uncertainty and potential financial penalties for ADMA Biologics. The downgrade by Cantor Fitzgerald further solidified negative sentiment, and the withdrawal of financial guidance by ADMA Biologics suggests a challenging outlook for the company.

biotechnology pharmaceuticals legal services
Event Summary

ADMA Biologics, a biopharmaceutical company, is facing multiple class action lawsuits and investigations by law firms such as Bleichmar Fonti & Auld LLP, Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Rosen Law Firm, Kahn Swick & Foti, and The Schall Law Firm. These legal actions stem from a report published by Culper Research on March 24, 2026, which alleged that ADMA Biologics engaged in a "channel stuffing" scheme and had an undisclosed related-party distributor to inflate its 2025 revenue growth. The report claimed that without this alleged scheme, ADMA Biologics would have experienced a 3% revenue decline instead of the reported 20% growth. Following this news, ADMA Biologics' stock price dropped by 29% over two trading days. Cantor Fitzgerald subsequently downgraded the company's stock, citing dissatisfaction with ADMA Biologics' response to the allegations. Additionally, ADMA Biologics withdrew its long-term financial guidance on May 6, 2026, further impacting investor confidence. The lawsuits allege that ADMA Biologics made false and misleading statements, engaged in undisclosed related-party transactions, used channel stuffing to create an appearance of revenue, and lacked adequate internal controls.

Key Actions
100 Lowey Dannenberg investigating ADMA Biologics
100 Glancy Prongay & Murray filed class action lawsuit ADMA Biologics
97 Rosen Law Firm announced investigation ADMA Biologics
97 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit ADMA Biologics
93 Kahn Swick & Foti notified investors of lawsuit ADMA Biologics
92 Culper Research published report ADMA Biologics
90 ADMA Biologics induced distributor stock
90 Bleichmar Fonti & Auld LLP announced investigation ADMA Biologics
90 Faruqi & Faruqi investigating claims against ADMA Biologics
90 Kessler Topaz Meltzer & Check filed lawsuit ADMA Biologics
90 The Schall Law Firm reminded investors of lawsuit ADMA Biologics
90 Robbins Geller Rudman & Dowd LLP announced class action ADMA Biologics
90 Kirby McInerney LLP filed lawsuit ADMA Biologics
88 Pomerantz LLP investigated claims ADMA Biologics
82 ADMA Biologics reported revenue growth
+ 4 more actions View on Dashboard
Entities Involved
stock
ADMA Biologics
ADMA Biologics is the primary subject of the class action lawsuits and investigations due to allegations of channel stuffing, undisclosed related-party transactions, and misleading revenue growth, which caused its stock price to decline significantly.
Importance 100.0 Sentiment -80.0
priv
Culper Research
Culper Research is the investigative firm that published a report alleging ADMA Biologics engaged in channel stuffing and had misleading revenue growth, triggering the stock drop and subsequent lawsuits.
Importance 90.0 Sentiment 60.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is a law firm that has filed a class action lawsuit against ADMA Biologics and its officers for alleged violations of federal securities laws.
Importance 70.0 Sentiment 20.0
priv
Rosen Law Firm
Rosen Law Firm is investigating potential securities claims and has filed a class action lawsuit against ADMA Biologics for allegedly issuing materially misleading business information.
Importance 70.0 Sentiment 20.0
priv
Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP is a law firm investigating ADMA Biologics for potential violations of federal securities laws and encouraging investors to join a class action lawsuit.
Importance 70.0 Sentiment 20.0
priv
Kahn Swick & Foti
Kahn Swick & Foti is a law firm that has notified investors of a class action securities lawsuit against ADMA Biologics.
Importance 65.0 Sentiment 20.0
priv
Pomerantz LLP
Pomerantz LLP is a law firm investigating claims on behalf of ADMA Biologics investors regarding potential securities fraud and unlawful business practices.
Importance 65.0 Sentiment 20.0
per
Andrea Farah
Andrea Farah, a partner at Lowey Dannenberg, is leading the firm's investigation into ADMA Biologics' alleged misconduct.
Importance 60.0 Sentiment 50.0
per
Vincent R. Cappucci Jr.
Vincent R. Cappucci Jr., an attorney at Lowey Dannenberg, is involved in the investigation of ADMA Biologics.
Importance 60.0 Sentiment 50.0
priv
Lowey Dannenberg
Lowey Dannenberg is a law firm investigating ADMA Biologics for potential violations of federal securities laws.
Importance 60.0 Sentiment 20.0
priv
The Schall Law Firm
The Schall Law Firm is a shareholder rights litigation firm reminding investors of a class action lawsuit against ADMA Biologics for violations of the Securities Exchange Act.
Importance 60.0 Sentiment 20.0
priv
Cantor Fitzgerald
Cantor Fitzgerald downgraded ADMA Biologics' stock, citing disappointment with the company's response to the Culper Research report, further contributing to the stock's decline.
Importance 40.0 Sentiment 0.0
govactor
United States — United States District Court for the District of New Jersey
The United States — United States District Court for the District of New Jersey is where the class action lawsuit against ADMA Biologics is pending.
Importance 40.0 Sentiment 0.0
per
Philip Kim
Phillip Kim is a contact person at Rosen Law Firm for investors interested in joining the prospective class action against ADMA Biologics.
Importance 30.0 Sentiment 40.0
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm, which is investigating ADMA Biologics for securities fraud.
Importance 30.0 Sentiment 40.0
+ 4 more entities View on Dashboard
Relationships
ADMA Biologics target ↔ Culper Research ADMA Biologics is the target of an activist short campaign by Culper Research, facing intense scrutiny and subsequent cl
ADMA Biologics related ↔ Rosen Law Firm
ADMA Biologics related ↔ Bleichmar Fonti & Auld LLP
ADMA Biologics related ↔ Kahn Swick & Foti
Culper Research related ↔ Bleichmar Fonti & Auld LLP
Bronstein, Gewirtz & Grossman, LLC competitor ↔ Rosen Law Firm Bronstein, Gewirtz & Grossman, LLC is a direct competitor to Rosen Law Firm in the plaintiff-side securities class actio
Bronstein, Gewirtz & Grossman, LLC related ↔ Bleichmar Fonti & Auld LLP
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Kahn Swick & Foti Bronstein, Gewirtz & Grossman, LLC frequently collaborates with Kahn Swick & Foti as co-counsel on numerous securities c
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Pomerantz LLP Bronstein, Gewirtz & Grossman, LLC frequently collaborates with Pomerantz LLP as co-plaintiffs in numerous class action
Rosen Law Firm related ↔ Bleichmar Fonti & Auld LLP
Rosen Law Firm related ↔ Kahn Swick & Foti
Rosen Law Firm competitor ↔ Pomerantz LLP Rosen Law Firm competes directly with Pomerantz LLP in the plaintiff-side securities litigation market, often investigat
Bleichmar Fonti & Auld LLP related ↔ Kahn Swick & Foti
Bleichmar Fonti & Auld LLP related ↔ Pomerantz LLP
Kahn Swick & Foti related ↔ Pomerantz LLP
+ 2 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.